The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs

H. Hata, Kensuke Egashira, T. Fukai, Y. Ohara, H. Kasuya, T. Takahashi, A. Takeshita

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The effects of an inhibitor of endothelium-derived nitric oxide on acetylcholine (ACh)-induced coronary vasoconstriction were examined in 13 anesthetized closed-chest pigs. Methods: Coronary blood flow was measured using a previously implanted ultrasonic transmit-time flow probe. The diameter of the large epicardial coronary arteries was assessed by coronary arteriography. Results: Intracoronary infusions of ACh (0.1, 0.3, and 1.0 μg/kg/min) resulted in dose-dependent decreases in coronary blood flow. Arterial pressure and heart rate were minimally altered by ACh. The high dose of ACh decreased coronary blood flow by 67 ± 11% and caused myocardial ischemia, demonstrated by ST-segment elevation. Coronary arteriograms revealed diffuse narrowing of peripheral coronary arteries and a filling delay of the contrast medium evoked with ACh. Vasospasm of the large epicardial coronary arteries was not observed. The decreases in coronary blood flow with ACh were inhibited by atropine (0.2 mg). Intracoronary administration of an inhibitor of endothelium-derived nitric oxide, N(W)- nitro-L-arginine (NNLA, 1.0 mg/kg), slightly increased arterial pressure but did not change baseline coronary blood flow. The percentage decreases in coronary blood flow induced by ACh were significantly augmented by NNLA administration, but those induced by prostaglandin F(2α) (0.5 μg/kg/min) were not affected by NNLA. The response of the large coronary arteries to ACh was not altered by NNLA. Conclusions: Our results suggest that, in pigs, ACh decreased coronary blood flow and caused myocardial ischemia as a result of the direct cholinergic vasoconstriction of peripheral small coronary arteries. The augmentation of ACh-induced coronary vasoconstriction by NNLA suggests that ACh facilitated the release of endothelium-derived nitric oxide, which attenuated the direct coronary vasoconstriction induced by ACh.

Original languageEnglish
Pages (from-to)891-898
Number of pages8
JournalCoronary Artery Disease
Volume4
Issue number10
DOIs
Publication statusPublished - Jan 1 1993

Fingerprint

Vasoconstriction
Acetylcholine
Nitric Oxide
Swine
Thorax
Coronary Vessels
Myocardial Ischemia
Arterial Pressure
Prostaglandins F
Atropine
Ultrasonics
Cholinergic Agents
Contrast Media
Arginine
Angiography
Heart Rate

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs. / Hata, H.; Egashira, Kensuke; Fukai, T.; Ohara, Y.; Kasuya, H.; Takahashi, T.; Takeshita, A.

In: Coronary Artery Disease, Vol. 4, No. 10, 01.01.1993, p. 891-898.

Research output: Contribution to journalArticle

Hata, H. ; Egashira, Kensuke ; Fukai, T. ; Ohara, Y. ; Kasuya, H. ; Takahashi, T. ; Takeshita, A. / The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs. In: Coronary Artery Disease. 1993 ; Vol. 4, No. 10. pp. 891-898.
@article{792caf3da892407894a96ca1bedf9bd2,
title = "The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs",
abstract = "Background: The effects of an inhibitor of endothelium-derived nitric oxide on acetylcholine (ACh)-induced coronary vasoconstriction were examined in 13 anesthetized closed-chest pigs. Methods: Coronary blood flow was measured using a previously implanted ultrasonic transmit-time flow probe. The diameter of the large epicardial coronary arteries was assessed by coronary arteriography. Results: Intracoronary infusions of ACh (0.1, 0.3, and 1.0 μg/kg/min) resulted in dose-dependent decreases in coronary blood flow. Arterial pressure and heart rate were minimally altered by ACh. The high dose of ACh decreased coronary blood flow by 67 ± 11{\%} and caused myocardial ischemia, demonstrated by ST-segment elevation. Coronary arteriograms revealed diffuse narrowing of peripheral coronary arteries and a filling delay of the contrast medium evoked with ACh. Vasospasm of the large epicardial coronary arteries was not observed. The decreases in coronary blood flow with ACh were inhibited by atropine (0.2 mg). Intracoronary administration of an inhibitor of endothelium-derived nitric oxide, N(W)- nitro-L-arginine (NNLA, 1.0 mg/kg), slightly increased arterial pressure but did not change baseline coronary blood flow. The percentage decreases in coronary blood flow induced by ACh were significantly augmented by NNLA administration, but those induced by prostaglandin F(2α) (0.5 μg/kg/min) were not affected by NNLA. The response of the large coronary arteries to ACh was not altered by NNLA. Conclusions: Our results suggest that, in pigs, ACh decreased coronary blood flow and caused myocardial ischemia as a result of the direct cholinergic vasoconstriction of peripheral small coronary arteries. The augmentation of ACh-induced coronary vasoconstriction by NNLA suggests that ACh facilitated the release of endothelium-derived nitric oxide, which attenuated the direct coronary vasoconstriction induced by ACh.",
author = "H. Hata and Kensuke Egashira and T. Fukai and Y. Ohara and H. Kasuya and T. Takahashi and A. Takeshita",
year = "1993",
month = "1",
day = "1",
doi = "10.1097/00019501-199310000-00008",
language = "English",
volume = "4",
pages = "891--898",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs

AU - Hata, H.

AU - Egashira, Kensuke

AU - Fukai, T.

AU - Ohara, Y.

AU - Kasuya, H.

AU - Takahashi, T.

AU - Takeshita, A.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background: The effects of an inhibitor of endothelium-derived nitric oxide on acetylcholine (ACh)-induced coronary vasoconstriction were examined in 13 anesthetized closed-chest pigs. Methods: Coronary blood flow was measured using a previously implanted ultrasonic transmit-time flow probe. The diameter of the large epicardial coronary arteries was assessed by coronary arteriography. Results: Intracoronary infusions of ACh (0.1, 0.3, and 1.0 μg/kg/min) resulted in dose-dependent decreases in coronary blood flow. Arterial pressure and heart rate were minimally altered by ACh. The high dose of ACh decreased coronary blood flow by 67 ± 11% and caused myocardial ischemia, demonstrated by ST-segment elevation. Coronary arteriograms revealed diffuse narrowing of peripheral coronary arteries and a filling delay of the contrast medium evoked with ACh. Vasospasm of the large epicardial coronary arteries was not observed. The decreases in coronary blood flow with ACh were inhibited by atropine (0.2 mg). Intracoronary administration of an inhibitor of endothelium-derived nitric oxide, N(W)- nitro-L-arginine (NNLA, 1.0 mg/kg), slightly increased arterial pressure but did not change baseline coronary blood flow. The percentage decreases in coronary blood flow induced by ACh were significantly augmented by NNLA administration, but those induced by prostaglandin F(2α) (0.5 μg/kg/min) were not affected by NNLA. The response of the large coronary arteries to ACh was not altered by NNLA. Conclusions: Our results suggest that, in pigs, ACh decreased coronary blood flow and caused myocardial ischemia as a result of the direct cholinergic vasoconstriction of peripheral small coronary arteries. The augmentation of ACh-induced coronary vasoconstriction by NNLA suggests that ACh facilitated the release of endothelium-derived nitric oxide, which attenuated the direct coronary vasoconstriction induced by ACh.

AB - Background: The effects of an inhibitor of endothelium-derived nitric oxide on acetylcholine (ACh)-induced coronary vasoconstriction were examined in 13 anesthetized closed-chest pigs. Methods: Coronary blood flow was measured using a previously implanted ultrasonic transmit-time flow probe. The diameter of the large epicardial coronary arteries was assessed by coronary arteriography. Results: Intracoronary infusions of ACh (0.1, 0.3, and 1.0 μg/kg/min) resulted in dose-dependent decreases in coronary blood flow. Arterial pressure and heart rate were minimally altered by ACh. The high dose of ACh decreased coronary blood flow by 67 ± 11% and caused myocardial ischemia, demonstrated by ST-segment elevation. Coronary arteriograms revealed diffuse narrowing of peripheral coronary arteries and a filling delay of the contrast medium evoked with ACh. Vasospasm of the large epicardial coronary arteries was not observed. The decreases in coronary blood flow with ACh were inhibited by atropine (0.2 mg). Intracoronary administration of an inhibitor of endothelium-derived nitric oxide, N(W)- nitro-L-arginine (NNLA, 1.0 mg/kg), slightly increased arterial pressure but did not change baseline coronary blood flow. The percentage decreases in coronary blood flow induced by ACh were significantly augmented by NNLA administration, but those induced by prostaglandin F(2α) (0.5 μg/kg/min) were not affected by NNLA. The response of the large coronary arteries to ACh was not altered by NNLA. Conclusions: Our results suggest that, in pigs, ACh decreased coronary blood flow and caused myocardial ischemia as a result of the direct cholinergic vasoconstriction of peripheral small coronary arteries. The augmentation of ACh-induced coronary vasoconstriction by NNLA suggests that ACh facilitated the release of endothelium-derived nitric oxide, which attenuated the direct coronary vasoconstriction induced by ACh.

UR - http://www.scopus.com/inward/record.url?scp=0027442357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027442357&partnerID=8YFLogxK

U2 - 10.1097/00019501-199310000-00008

DO - 10.1097/00019501-199310000-00008

M3 - Article

C2 - 8269195

AN - SCOPUS:0027442357

VL - 4

SP - 891

EP - 898

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 10

ER -